GALDERMA GROUP AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.53 CHF | -0.97% |
|
-1.49% | 0.00% |
| May. 23 | Galderma Group AG Launches Restylane VOLYME in China | CI |
| May. 15 | Ten key beauty players |  |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 19,330 | - | - |
| Enterprise Value (EV) 1 | 21,637 | 21,137 | 20,435 |
| P/E ratio | 92.9 x | 39.2 x | 25.3 x |
| Yield | 0.12% | 0.34% | 0.6% |
| Capitalization / Revenue | 4.39 x | 3.89 x | 3.41 x |
| EV / Revenue | 4.91 x | 4.26 x | 3.61 x |
| EV / EBITDA | 21.2 x | 18.2 x | 14.3 x |
| EV / FCF | 301 x | 46.5 x | 30.3 x |
| FCF Yield | 0.33% | 2.15% | 3.3% |
| Price to Book | 2.48 x | 2.35 x | 2.18 x |
| Nbr of stocks (in thousands) | 237,898 | - | - |
| Reference price 2 | 81.25 | 81.25 | 81.25 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net sales 1 | 4,406 | 4,964 | 5,668 |
| EBITDA 1 | 1,023 | 1,159 | 1,426 |
| EBIT 1 | 677.1 | 1,021 | 1,307 |
| Operating Margin | 15.37% | 20.56% | 23.06% |
| Earnings before Tax (EBT) 1 | 323 | 612.5 | 943 |
| Net income 1 | 205.7 | 468 | 749 |
| Net margin | 4.67% | 9.43% | 13.21% |
| EPS 2 | 0.8746 | 2.071 | 3.212 |
| Free Cash Flow 1 | 72 | 455 | 674 |
| FCF margin | 1.63% | 9.17% | 11.89% |
| FCF Conversion (EBITDA) | 7.04% | 39.26% | 47.28% |
| FCF Conversion (Net income) | 35% | 97.21% | 89.99% |
| Dividend per Share 2 | 0.0979 | 0.2757 | 0.4850 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net Debt 1 | 2,307 | 1,807 | 1,105 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | 2.256 x | 1.56 x | 0.7748 x |
| Free Cash Flow 1 | 72 | 455 | 674 |
| ROE (net income / shareholders' equity) | 6.86% | 8.55% | 10.6% |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets 1 | - | - | - |
| Book Value Per Share 2 | 32.80 | 34.60 | 37.20 |
| Cash Flow per Share 2 | 32.60 | 18.70 | 4.240 |
| Capex 1 | 330 | 166 | 188 |
| Capex / Sales | 7.49% | 3.35% | 3.32% |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
81.25
USD
Average target price
85.71
USD
Spread / Average Target
+5.48%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 19.33B | |
| -0.81% | 261B | |
| +20.26% | 20.62B | |
| +17.12% | 12.66B | |
| -15.06% | 9.11B | |
| +22.28% | 8.21B | |
| +12.97% | 6.12B | |
| -9.53% | 4.09B | |
| -17.45% | 3.81B | |
| -0.89% | 3.73B |
- Stock Market
- Equities
- GALD Stock
- Financials Galderma Group AG
